Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Concord Biotech Limited (NSE: CONCORDBIO), ISIN INE338H01029 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
CONCORDBIO last traded at ₹1559.20 (+1.87%), with a 52-week range of ₹987.05 to ₹1674.85 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 44.08%, FIIs 7.52%, DIIs 9.36%, mutual funds 4.40%.
EquiSense Score (ECS): 80/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.